Jeffrey F. McKelvey
Profile
Jeffrey F.
McKelvey is a Director of KineMed, Inc. as well as President and Chief Technology Officer of Avera Pharmaceuticals.
Before joining Avera, he was Vice President of Merck Research Laboratories.
He joined SIBIA Neurosciences, Inc. in 1998 as Executive Vice President, Chief Scientific Officer and a Director.
Previously, he was Founding Chief Executive Officer of Trophix Pharmaceuticals, Inc. Dr. McKelvey is an Adjunct Professor of Psychiatry at the University of California, San Diego.
Former positions of Jeffrey F. McKelvey
Companies | Position | End |
---|---|---|
Trophix Pharmaceuticals, Inc.
Trophix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of NPS Allelix Corp., Trophix Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in South Plainfield, NJ. The company was founded by Jeffrey F. McKelvy. Trophix Pharmaceuticals was acquired by Allelix Biopharmaceuticals, Inc. on July 30, 1997 for $27 million. | President | - |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Corporate Officer/Principal | - |
Sibia Neurosciences, Inc. | Chief Tech/Sci/R&D Officer | - |
KINEMED INC | Director/Board Member | - |
Experiences
Positions held
Linked companies
Private companies | 4 |
---|---|
KineMed, Inc.
KineMed, Inc. Miscellaneous Commercial ServicesCommercial Services KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA. | Commercial Services |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
Sibia Neurosciences, Inc. | Health Technology |
Trophix Pharmaceuticals, Inc.
Trophix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of NPS Allelix Corp., Trophix Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in South Plainfield, NJ. The company was founded by Jeffrey F. McKelvy. Trophix Pharmaceuticals was acquired by Allelix Biopharmaceuticals, Inc. on July 30, 1997 for $27 million. | Health Technology |
- Stock Market
- Insiders
- Jeffrey F. McKelvey